Relmada Therapeutics (RLMD) Other Operating Expenses (2012 - 2022)
Relmada Therapeutics (RLMD) posted quarterly Other Operating Expenses of $6.4 million for Q2 2022, up 878407.05% quarter-over-quarter from $723.0 in Q1 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Other Operating Expenses (2012 - 2022) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Other Operating Expenses for 3 consecutive years, with $6.4 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Other Operating Expenses changed N/A year-over-year to $6.4 million; the TTM figure through Mar 2023 stood at $6.4 million (changed N/A YoY), while the FY2022 annual figure was $6.4 million, changed N/A from the prior year.
- Other Operating Expenses climbed to $6.4 million in Q2 2022 per RLMD's latest filing, from $723.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $6.4 million in Q2 2022 and bottomed at $6.4 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 6.35 Mn |
| Feb 28, 2013 | 723.00 |
| Nov 30, 2012 | 309.00 |
| Aug 31, 2012 | 1,048.00 |